Orchestra BioMed Holdings, Inc. (OBIO) Analyst Estimates & Price Targets

Orchestra BioMed Holdings, Inc. (OBIO) — Price $6.01 HealthcareBiotechnology — NASDAQ

Latest reported results:

Wall Street analyst estimates for Orchestra BioMed Holdings, Inc. (OBIO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.

Valuation Ratios

Price / Book11.92
EV / EBITDA-5.85
Dividend Yield0.00%

Income Statement (10y)

Year202020212022202320242025
Revenue$5.7M-$782000$3.5M$2.8M$2.6M$33.5M
Cost of Revenue$145000$199000$322000$186000$204000$190000
Gross Profit$5.6M-$981000$3.2M$2.6M$2.4M$33.3M
Research & Development$13.5M$12.9M$21.9M$33.8M$42.8M$58.2M
Selling, General & Admin$10.8M$7.9M$13.9M$20.3M$23.9M$26.9M
Operating Expenses$24.3M$20.8M$35.9M$54.1M$66.7M$85.1M
Operating Income-$18.8M-$21.8M-$32.7M-$51.5M-$64.3M-$51.8M
EBITDA-$18.6M-$21.9M-$33.4M-$48.8M-$60.7M-$51.2M
Interest Expense0$927000000$1.1M
Pre-tax Income-$21.4M-$23.0M-$33.6M-$49.1M-$61.0M-$52.7M
Income Tax000000
Net Income-$21.4M-$23.0M-$33.6M-$49.1M-$61.0M-$52.7M
EPS$-0.01$-0.02$-1.32$-1.48$-1.66$-1.11
EPS (Diluted)$-0.01$-0.02$-1.32$-1.48$-1.66$-1.11
Shares Outstanding (Diluted)$20.4M$20.4M$25.5M$33.2M$36.8M$47.7M

Price

Price$6.01
Market Cap$360M
ExchangeNASDAQ
CountryUS

Related companies: AVTX · CRBU · ENTA · EPRX · IVA · IVVD · PRLD

Explore sector: Healthcare · Biotechnology

More sections of OBIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks